These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 38196001)

  • 1. Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson's disease.
    Naoi M; Maruyama W; Shamoto-Nagai M; Riederer P
    J Neural Transm (Vienna); 2024 Jun; 131(6):639-661. PubMed ID: 38196001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.
    Naoi M; Maruyama W; Shamoto-Nagai M
    J Neural Transm (Vienna); 2020 Feb; 127(2):131-147. PubMed ID: 31993732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies.
    Naoi M; Maruyama W; Shamoto-Nagai M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
    Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
    J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dietary Natural Flavonoids: Intervention for MAO-B Against Parkinson's Disease.
    Singh A; Sinha S; Singh NK
    Chem Biol Drug Des; 2024 Sep; 104(3):e14619. PubMed ID: 39223743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective and toxic roles of dopamine in Parkinson's disease.
    Segura-Aguilar J; Paris I; Muñoz P; Ferrari E; Zecca L; Zucca FA
    J Neurochem; 2014 Jun; 129(6):898-915. PubMed ID: 24548101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine oxidase and α-synuclein as targets in Parkinson's disease therapy.
    Follmer C
    Expert Rev Neurother; 2014 Jun; 14(6):703-16. PubMed ID: 24852232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease.
    Kang SS; Ahn EH; Zhang Z; Liu X; Manfredsson FP; Sandoval IM; Dhakal S; Iuvone PM; Cao X; Ye K
    EMBO J; 2018 Jun; 37(12):. PubMed ID: 29769405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-modifying treatment of Parkinson's disease by phytochemicals: targeting multiple pathogenic factors.
    Naoi M; Maruyama W; Shamoto-Nagai M
    J Neural Transm (Vienna); 2022 Jun; 129(5-6):737-753. PubMed ID: 34654977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
    Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ
    Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
    Nagatsu T; Sawada M
    J Neural Transm Suppl; 2006; (71):53-65. PubMed ID: 17447416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.
    Goldstein DS
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting α-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease.
    Haque ME; Akther M; Azam S; Kim IS; Lin Y; Lee YH; Choi DK
    Br J Pharmacol; 2022 Jan; 179(1):23-45. PubMed ID: 34528272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
    Zuo L; Motherwell MS
    Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-synuclein, lipids and Parkinson's disease.
    Ruipérez V; Darios F; Davletov B
    Prog Lipid Res; 2010 Oct; 49(4):420-8. PubMed ID: 20580911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.
    Luo Z; Ahlers-Dannen KE; Spicer MM; Yang J; Alberico S; Stevens HE; Narayanan NS; Fisher RA
    JCI Insight; 2019 May; 5(13):. PubMed ID: 31120439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease.
    Petit GH; Berkovich E; Hickery M; Kallunki P; Fog K; Fitzer-Attas C; Brundin P
    PLoS One; 2013; 8(4):e60691. PubMed ID: 23573275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson's disease. An integrated strategy for management.
    Phillipson OT
    Ageing Res Rev; 2017 Nov; 40():149-167. PubMed ID: 28986235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.